Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 174 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Organ Transplants Clear all
Terminated Phase 2 Interventional Results available

Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients

NCT03617445
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
FMT oral capsule, Oral Vancomycin, FMT oral placebo, Oral Vancomycin placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 9:57 AM EDT
Recruiting Early Phase 1 Interventional

A Randomized Controlled Trial of Topical 5% Niacinamide for Skin Cancer Prevention in Transplant Recipients

NCT07286318
View directory record Official record
Conditions
Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Actinic Keratosis (AK), Organ Transplant Recipient
Interventions
Topical niacinamide 5% cream, Sunscreen
Drug
Lead sponsor
Marissa Lobl
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 9:57 AM EDT
Completed No phase listed Observational

Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients

NCT02602262
View directory record Official record
Conditions
HIV Infection
Interventions
HIV-infected deceased donor organ
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
18
States / cities
Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cemiplimab in AlloSCT/SOT Recipients With CSCC

NCT04339062
View directory record Official record
Conditions
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Interventions
Cemiplimab, Everolimus, Sirolimus, Prednisone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 21, 2026, 9:57 AM EDT
Completed No phase listed Observational

Continuous Hemoglobin Monitoring in Pediatric Transplant

NCT00958984
View directory record Official record
Conditions
Pediatric Solid Organ Transplant
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
Up to 18 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Donor Designation Rates in Teenagers: Effectiveness of a Driver's Education Intervention

NCT03013816
View directory record Official record
Conditions
Organ Donor Registration, Organ Donation Education
Interventions
Organ Donation Education: Testimonial Messaging, Organ Donation Education: Informational Messaging, Organ Donation Education: Blended Messaging
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00276588
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Bortezomib Plus Rituximab for EBV+ PTLD

NCT01058239
View directory record Official record
Conditions
Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections
Interventions
bortezomib, rituximab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2018 · Synced Oct 21, 2026, 9:57 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Performance Comparison of QuantiFERON Monitor in Solid Organ Transplant Recipients

NCT02416414
View directory record Official record
Conditions
Cell-mediated Immune Response
Interventions
QuantiFERON Monitor Assay, Existing methodology
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2016 · Synced Oct 21, 2026, 9:57 AM EDT
Completed No phase listed Observational

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

NCT05164016
View directory record Official record
Conditions
Cancer, Hematopoietic System--Cancer, Transplant-Related Cancer, Solid Tumor Malignancy, Hematologic Malignancy, Solid Organ Transplant, Hematopoietic Cell Transplant, Cellular Therapy
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Wellness Interventions After Transplant Study

NCT00367809
View directory record Official record
Conditions
Organ Transplant
Interventions
Mindfulness-Based Stress Reduction (MSBR), Health Education (HE), Delayed Intervention
Behavioral
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2008 · Synced Oct 21, 2026, 9:57 AM EDT
Completed No phase listed Observational

Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease

NCT00904579
View directory record Official record
Conditions
Immunocompromised Host, Organ Transplantation, Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 100 Years
Enrollment
19,929,901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
9
States / cities
Sacramento, California • Denver, Colorado • Hartford, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 21, 2026, 9:57 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

NCT01685372
View directory record Official record
Conditions
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT), Dialysis
Interventions
Fluzone High Dose, Fluzone
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
5 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 21, 2026, 9:57 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

NCT04807777
View directory record Official record
Conditions
Advanced Cutaneous Squamous Cell Carcinoma
Interventions
Ruxolitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 21, 2026, 9:57 AM EDT
Recruiting Phase 2 Interventional

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

NCT06552169
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
Drug · Biological
Lead sponsor
Singulera Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional

Deceased Organ Donor Interventions to Protect Kidney Graft Function

NCT02525510
View directory record Official record
Conditions
Brain Death, Organ Donation, Organ Transplant Failure or Rejection, Delayed Graft Function
Interventions
Pump Eligible - Normothermia - Pump Both Kidneys, Pump Eligible - Hypothermia and Pump Right Kidney, Pump Eligible - Hypothermia and Pump Left Kidney, Not Pump Eligible - Normothermia, Not Pump Eligible - Hypothermia
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1,427 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
7
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 2 Interventional Results available

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

NCT01329185
View directory record Official record
Conditions
EBV Viremia, CMV Viremia
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
6 Months and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study

NCT03626714
View directory record Official record
Conditions
Organ Transplant Rejection, Psoriasis
Interventions
Sustained Release Injectable Tacrolimus
Drug
Lead sponsor
Auritec Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 21, 2026, 9:57 AM EDT
Recruiting No phase listed Observational

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

NCT05550298
View directory record Official record
Conditions
Hematopoietic Cell Transplant, Solid Organ Transplant, Respiratory Viral Infection
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 18 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Washington D.C., District of Columbia + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 21, 2026, 9:57 AM EDT
Active, not recruiting Phase 4 Interventional

Immunogenicity of HPV Vaccine in Transplant Recipients.

NCT05557370
View directory record Official record
Conditions
Chronic Kidney Diseases, Kidney Transplant
Interventions
Human Papilloma Virus vaccine (GARDASIL 9)
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 21, 2026, 9:57 AM EDT
Terminated Not applicable Interventional Results available

Domperidone for Gastroparesis in Solid Organ Transplantation

NCT00552422
View directory record Official record
Conditions
Gastroparesis, Gastroesophageal Reflux
Interventions
domperidone
Drug
Lead sponsor
David J. Lederer, M.D.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Phase 1 Interventional

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT05121142
View directory record Official record
Conditions
Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant
Interventions
Ruxolitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 21, 2026, 9:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Creating a Patient-centered Report Card for Solid Organ Transplant Candidates

NCT03610555
View directory record Official record
Conditions
Transplants
Interventions
Intervention 1 - SRTR (age question 1st), Intervention 2 - SRTR (BMI question 1st), Intervention 3 - TCST (age question 1st), Intervention 4 - TCST (BMI question 1st)
Other
Lead sponsor
Ajay Israni, MD
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 21, 2026, 9:57 AM EDT